The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells1

Journal of Immunology

Volumn 180, Issue 8, 2008, Pages 5402-5412

  Seubert, Anja ^a   Monaci, Elisabetta ^a   Pizza, Mariagrazia ^a   O'hagan, Derek T ^a   Wack, Andreas ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; BETA CHEMOKINE; CD14 ANTIGEN; HLA ANTIGEN CLASS 2; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENDOCYTOSIS; GRANULOCYTE; HUMAN; HUMAN CELL; LYMPH NODE; MACROPHAGE; MOLECULAR MECHANICS; MOLECULAR MODEL; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; SUPERNATANT; UPREGULATION; VACCINATION; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; METABOLISM;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANTIGENS, CD14; ANTIGENS, CD86; CELL DIFFERENTIATION; CHEMOKINES, CC; DENDRITIC CELLS; ENDOCYTOSIS; GRANULOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MONOCYTES; POLYSORBATES; SQUALENE;

EID: 45949083618     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.8.5402     Document Type: Article

References (38)

1. O'Hagan, D. T., and N. M. Valiante. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2: 727-735.
2. Medzhitov, R., and C. A. Janeway, Jr. 1997. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91: 295-298.
3. Fearon, D. T., and R. M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 272: 50-53.
4. O'Hagan, D. T., G. S. Ott, and G. Van Nest. 1997. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol. Med. Today 3: 69-75.
5. Podda, A., and G. Del Giudice. 2006. MF59: a safe and potent adjuvant for human use. In Immunopotentiators in Modern Vaccines. V. E. Schijns, and D. T. O'Hagan, eds. Academic Press, Oxford, p. 149.
6. Gupta, R. K., B. E. Rost, E. Relyveld, and G. R. Siber. 1995. Adjuvant properties of aluminum and calcium compounds. Pharm. Biotechnol. 6: 229-248.
7. Podda, A. 2001. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19: 2673-2680.
8. Alderson, M. R., P. McGowan, J. R. Baldridge, and P. Probst. 2006. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res. 12: 313-319.
9. Podda, A., and G. Del Giudice. 2003. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2: 197-203.
10. Singh, M., M. Ugozzoli, J. Kazzaz, J. Chesko, E. Soenawan, D. Mannucci, F. Titta, M. Contorni, G. Volpini, G. Del Guidice, and D. T. O'Hagan. 2006. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 10: 1680-1686.
11. Mannhalter, J. W., H. O. Neychev, G. J. Zlabinger, R. Ahmad, and M. M. Eibl. 1985. Modulation of the human immune response by the non-toxic and nonpyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin. Exp. Immunol. 61: 143-151.
12. Ulanova, M., A. Tarkowski, M. Hahn-Zoric, and L. A. Hanson. 2001. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. 69: 1151-1159.
13. Rimaniol, A. C., G. Gras, F. Verdier, F. Capel, V. B. Grigoriev, F. Porcheray, E. Sauzeat, J. G. Fournier, P. Clayette, C. A. Siegrist, and D. Dormont. 2004. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22: 3127-3135.
14. Jordan, M. B., D. M. Mills, J. Kappler, P. Marrack, and J. C. Cambier. 2004. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304: 1808-1810.
15. Gordon, S., and P. R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5: 953-964.
16. Dupuis, M., D. M. McDonald, and G. Ott. 1999. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 18: 434-439.
17. Dupuis, M., K. Denis-Mize, A. LaBarbara, W. Peters, I. F. Charo, D. M. McDonald, and G. Ott. 2001. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur. J. Immunol. 31: 2910-2918.
18. Dupuis, M., T. J. Murphy, D. Higgins, M. Ugozzoli, G. van Nest, G. Ott, and D. M. McDonald. 1998. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol. 186: 18-27.
19. Dauer, M., B. Obermaier, J. Herten, C. Haerle, K. Pohl, S. Rothenfusser, M. Schnurr, S. Endres, and A. Eigler. 2003. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170: 4069-4076.
20. Gavin, A. L., K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and D. Nemazee. 2006. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314: 1936-1938.
21. Pimorady-Esfahani, A., M. D. Grounds, and P. G. McMenamin. 1997. Macrophages and dendritic cells in normal and regenerating murine skelet al. muscle. Muscle Nerve 20: 158-166.
22. Honda, H., H. Kimura, and A. Rostami. 1990. Demonstration and phenotypic characterization of resident macrophages in rat skelet al. muscle. Immunology 70: 272-277.
23. Boring, L., J. Gosling, S. W. Chensue, S. L. Kunkel, R. V. Farese, Jr., H. E. Broxmeyer, and I. F. Charo. 1997. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100: 2552-2561.
24. Randolph, G. J., S. Beaulieu, S. Lebecque, R. M. Steinman, and W. A. Muller. 1998. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 282: 480-483.
25. Chomarat, P., J. Banchereau, J. Davoust, and A. K. Palucka. 2000. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1: 510-514.
26. Palucka, K. A., N. Taquet, F. Sanchez-Chapuis, and J. C. Gluckman. 1999. Lipopolysaccharide can block the potential of monocytes to differentiate into dendritic cells. J. Leukocyte Biol. 65: 232-240.
27. Assier, E., V. Marin-Esteban, A. Haziot, E. Maggi, D. Charron, and N. Mooney. 2007. TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation. J. Leukocyte Biol. 81: 221-228.
28. Bartz, H., N. M. Avalos, A. Baetz, K. Heeg, and A. H. Dalpke. 2006. Involvement of suppressors of cytokine signaling in toll-like receptor-mediated block of dendritic cell differentiation. Blood 108: 4102-4108.
29. Fearon, D. T. 1997. Seeking wisdom in innate immunity. Nature 388: 323-324.
30. Rotta, G., E. W. Edwards, S. Sangaletti, C. Bennett, S. Ronzoni, M. P. Colombo, R. M. Steinman, G. J. Randolph, and M. Rescigno. 2003. Lipopolysaccharide or whole bacteria block the conversion of inflammatory monocytes into dendritic cells in vivo. J. Exp. Med. 198: 1253-1263.
31. Palucka, K. A., N. Taquet, F. Sanchez-Chapuis, and J. C. Gluckman. 1998. Dendritic cells as the terminal stage of monocyte differentiation. J. Immunol. 160: 4587-4595.
32. Zou, W., J. Borvak, F. Marches, S. Wei, P. Galanaud, D. Emilie, and T. J. Curiel. 2000. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by β-chemokines rather than IL-12. J. Immunol. 165: 4388-4396.
33. Luft, T., E. Maraskovsky, M. Schnurr, K. Knebel, M. Kirsch, M. Gorner, R. Skoda, A. D. Ho, P. Nawroth, and A. Bierhaus. 2004. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. Blood 104: 1066-1074.
34. Luft, T., M. Jefford, P. Luetjens, T. Toy, H. Hochrein, K. A. Masterman, C. Maliszewski, K. Shortman, J. Cebon, and E. Maraskovsky. 2002. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood 100: 1362-1372.
35. Sánchez-Sánchez, N., L. Riol-Blanco, and J. L. Rodríguez-Fernández. 2006. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 176: 5153-5159.
36. + T cell-dendritic cell interaction. Nature 440: 890-895.
37. O'Hagan, D. T., A. Wack, and A. Podda. 2007. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Ther. 82: 740-744.
38. Rimaniol, A. C, G. Gras, and P. Clayette. 2007. In vitro interactions between macrophages and aluminum-containing adjuvants. Vaccine 25: 6784-6792.